Drug updated on 11/10/2023
|Tablet (oral; 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide)
| Ongoing and
- For the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya.
Product Monograph / Prescribing Information
|Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) Prescribing Information.
|Gilead Sciences, Inc., Foster City, CA